Healthcare - Medical - Healthcare Plans - NASDAQ - US
$ 3.04
-1.3 %
$ 1.52 B
Market Cap
-16.0
P/E
Clover Health Investments, Corp. operates as a medicare advantage insurer in the United States. The company through its Clover Assistant, a software platform that provides preferred provider organization and health maintenance organization health plans for medicare-eligible consumers. It also focuses on non-insurance businesses. Clover Health Investments, Corp. was incorporated in 2014 and is based in Franklin, Tennessee.[ Read More ]
The intrinsic value of one CLOV stock under the base case scenario is HIDDEN Compared to the current market price of 3.04 USD, Clover Health Investments, Corp. is HIDDEN
2. FUNDAMENTAL
ANALYSIS
Price Chart CLOV
FINANCIALS
2.03 B
REVENUE
-209 M
OPERATING INCOME
-213 M
NET INCOME
-116 M
OPERATING CASH FLOW
140 M
INVESTING CASH FLOW
-33.9 M
FINANCING CASH FLOW
331 M
REVENUE
-8.78 M
OPERATING INCOME
-4.92 M
NET INCOME
58.8 M
OPERATING CASH FLOW
-12.1 M
INVESTING CASH FLOW
-4.67 M
FINANCING CASH FLOW
Balance Sheet Decomposition
Clover Health Investments, Corp.
| Current Assets | 428 M |
| Cash & Short-Term Investments | 243 M |
| Receivables | 114 M |
| Other Current Assets | 71.5 M |
| Non-Current Assets | 143 M |
| Long-Term Investments | 120 M |
| PP&E | 8.46 M |
| Other Non-Current Assets | 14.4 M |
| Current Liabilities | 261 M |
| Accounts Payable | 94.3 M |
| Short-Term Debt | 1.66 M |
| Other Current Liabilities | 165 M |
| Non-Current Liabilities | 23.2 M |
| Long-Term Debt | 3 M |
| Other Non-Current Liabilities | 20.2 M |
EFFICIENCY
Earnings Waterfall
Clover Health Investments, Corp.
| Revenue | 2.03 B |
| Cost Of Revenue | 1.78 B |
| Gross Profit | 257 M |
| Operating Expenses | 1.99 B |
| Operating Income | -209 M |
| Other Expenses | 4.82 M |
| Net Income | -213 M |
RATIOS
12.65%
GROSS MARGIN
-10.25%
OPERATING MARGIN
-10.49%
NET MARGIN
-74.50%
ROE
-37.39%
ROA
-72.82%
ROIC
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Clover Health Investments, Corp.
| Net Income | -213 M |
| Depreciation & Amortization | 2.51 M |
| Capital Expenditures | -584 K |
| Stock-Based Compensation | 141 M |
| Change in Working Capital | -55.4 M |
| Others | -50.7 M |
| Free Cash Flow | -116 M |
Wall Street Analysts Price Targets
Clover Health Investments, Corp.
Wall Street analysts predict an average 1-year price target for CLOV of $2.5 , with forecasts ranging from a low of $2.5 to a high of $2.5 .
CLOV Lowest Price Target
Wall Street Target
2.5 USD
-17.76%
CLOV Average Price Target
Wall Street Target
2.5 USD
-17.76%
CLOV Highest Price Target
Wall Street Target
2.5 USD
-17.76%
4. DIVIDEND ANALYSIS
0.00%
DIVIDEND YIELD
0 USD
DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership
Clover Health Investments, Corp.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
2.03 M USD 2
3-6 MONTHS
110 K USD 1
6-9 MONTHS
0 USD 0
9-12 MONTHS
| Date | Value | Insider | Amount | Avg Price |
|---|---|---|---|---|
|
3 months ago
Aug 09, 2024
|
Bought 1 M USD
|
Garipalli Vivek
director, 10 percent owner: |
+ 531700
|
1.88 USD |
|
5 months ago
Jun 17, 2024
|
Bought 1 M USD
|
Garipalli Vivek
director, 10 percent owner: |
+ 877567
|
1.14 USD |
|
6 months ago
May 16, 2024
|
Bought 15 K USD
|
Loengard Anna U
Director |
+ 15600
|
0.96 USD |
|
6 months ago
May 16, 2024
|
Bought 1.4 K USD
|
Loengard Anna U
Director |
+ 1485
|
0.94 USD |
|
6 months ago
May 17, 2024
|
Bought 9.3 K USD
|
Loengard Anna U
Director |
+ 10000
|
0.93 USD |
|
8 months ago
Mar 14, 2024
|
Bought 100 K USD
|
Loengard Anna U
Director |
+ 137000
|
0.73 USD |
|
8 months ago
Mar 14, 2024
|
Bought 9.95 K USD
|
Loengard Anna U
Director |
+ 13625
|
0.73 USD |
|
1 year ago
Sep 06, 2023
|
Bought 13 K USD
|
Loengard Anna U
Director |
+ 10000
|
1.3 USD |
|
1 year ago
Sep 06, 2023
|
Bought 650 USD
|
Loengard Anna U
Director |
+ 500
|
1.3 USD |
|
1 year ago
Sep 06, 2023
|
Bought 650 USD
|
Loengard Anna U
Director |
+ 500
|
1.3 USD |
|
2 years ago
Mar 11, 2022
|
Bought 248 K USD
|
SHAPIRO LEE
director: |
+ 80000
|
3.1009 USD |
|
2 years ago
Mar 03, 2022
|
Bought 253 K USD
|
Clinton Chelsea
director: |
+ 100000
|
2.5253 USD |
|
2 years ago
Nov 22, 2021
|
Bought 10 M USD
|
Palihapitiya Chamath
10 percent owner |
+ 1739130
|
5.75 USD |
7. News
Down -26.32% in 4 Weeks, Here's Why Clover Health Investments (CLOV) Looks Ripe for a Turnaround
Clover Health Investments (CLOV) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
zacks.com
- 1 day ago
Down -25.82% in 4 Weeks, Here's Why Clover Health Investments (CLOV) Looks Ripe for a Turnaround
The heavy selling pressure might have exhausted for Clover Health Investments (CLOV) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
zacks.com
- 2 days ago
Bears are Losing Control Over Clover Health Investments (CLOV), Here's Why It's a 'Buy' Now
After losing some value lately, a hammer chart pattern has been formed for Clover Health Investments (CLOV), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
zacks.com
- 4 days ago
CLOV Stock Declines Despite Q3 Earnings Beat, FY24 View Revised
Clover Health's third-quarter 2024 results continue to benefit from the strength of its business model.
zacks.com
- 1 week ago
Clover Health Investments, Corp. (CLOV) Reports Q3 Loss, Lags Revenue Estimates
Clover Health Investments, Corp. (CLOV) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to loss of $0.09 per share a year ago.
zacks.com
- 1 week ago
Clover Health Investments, Corp. (CLOV) Q3 2024 Earnings Call Transcript
Clover Health Investments, Corp. (NASDAQ:CLOV ) Q3 2024 Earnings Conference Call November 6, 2024 5:00 PM ET Company Participants Ryan Schmidt - Investor Relations Andrew Toy - Chief Executive Officer Peter Kuipers - Chief Financial Officer Conference Call Participants Jonathan Yong - UBS John French - Leerink Partners Operator Ladies and gentlemen, good afternoon. And welcome to the Clover Health Third Quarter 2024 Earnings Conference Call.
seekingalpha.com
- 1 week ago
Clover Health's Rally: The Payoff Of A Profitable Pivot
Clover Health's pivot to profitability over growth following the divestiture of the non-insurance segment at the end of 2023 has led to significant earnings improvements. The newly launched Counterpart Health platform could diversify the company's revenue, offsetting risks from declining Medicare Advantage memberships. The company has a strong balance sheet with no long-term debt and high liquidity ratios.
seekingalpha.com
- 1 week ago
CLOV Q3 Estimates Unchanged Before Earnings: How to Play the Stock?
The continued strength in Clover Health's offerings is likely to have driven the company's performance in the third quarter.
zacks.com
- 1 week ago
Clover Health to Report Third Quarter 2024 Financial Results on November 6
FRANKLIN, Tenn., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover Health”), today announced that it will report third quarter 2024 financial results after market close on Wednesday, November 6, 2024. Management will host a conference call and webcast at 5:00 p.m. Eastern Time on November 6, 2024, to discuss Clover Health's third quarter 2024 business and financial results.
globenewswire.com
- 3 weeks ago
2025 Clover Health Medicare Advantage Benefits Demonstrate Commitment to New Jersey Seniors
Company's affordable, benefit-rich flagship PPO plans now have 4 Star rating Company's affordable, benefit-rich flagship PPO plans now have 4 Star rating
globenewswire.com
- 1 month ago
Clover Health PPO Medicare Advantage Plans Earn 4 Star Rating for 2025
Overall Star rating performance increase was driven by exceptional performance on healthcare quality measures, Medication Adherence and Member Experience Overall Star rating performance increase was driven by exceptional performance on healthcare quality measures, Medication Adherence and Member Experience
globenewswire.com
- 1 month ago
Counterpart Health Names David Tsay M.D., Ph.D as Chief Medical Officer
Dr. Tsay Brings Unique Expertise in AI, Digital Health, and Clinical Innovation to Counterpart Health Dr. Tsay Brings Unique Expertise in AI, Digital Health, and Clinical Innovation to Counterpart Health
globenewswire.com
- 1 month ago
8. Profile Summary
Clover Health Investments, Corp. CLOV
COUNTRY
US
INDUSTRY
Medical - Healthcare Plans
MARKET CAP
$ 1.52 B
Dividend Yield
0.00%
Description
Clover Health Investments, Corp. operates as a medicare advantage insurer in the United States. The company through its Clover Assistant, a software platform that provides preferred provider organization and health maintenance organization health plans for medicare-eligible consumers. It also focuses on non-insurance businesses. Clover Health Investments, Corp. was incorporated in 2014 and is based in Franklin, Tennessee.
Contact
725 Cool Springs Blvd, Franklin, TN, 37067
https://www.cloverhealth.com
IPO Date
June 12, 2020
Employees
552
Officers
Ms. Jamie L. Reynoso
Chief Executive Officer of Medicare Advantage
Mr. Conrad Wai
Chief Technology Officer
Mr. Peter J. Kuipers
Chief Financial Officer
Ms. Rachel Fish
Chief People Officer
Mr. Derrick L. Nueman
Head of Investor Relations & Corporate strategy
Ms. Wendy Richey
Chief Compliance Officer
Mr. Vivek Garipalli
Co-Founder & Executive Chairman
Mr. Andrew Toy
Co-Founder, Chief Executive Officer & Director
Ms. Karen Soares
General Counsel, Senior Vice President & Corporate Secretary
Mr. Brady Priest J.D.
Chief Executive Officer of Home Care